We are live on ! Find out more
CLLS icon

Cellectis

0.9209 USD
-0.0629
6.39%
At close Updated Nov 20, 4:00 PM EST
1 day
-6.39%
5 days
-19.22%
1 month
-6.98%
3 months
-73.46%
6 months
-74.84%
Year to date
-80.81%
1 year
-80.73%
5 years
-88.98%
10 years
-94.88%
 

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 3.1%
Neutral 87.5%
Negative 9.4%
Neutral
Seeking Alpha
9 days ago
Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript
Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript
Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript
Positive
MarketBeat
9 days ago
What Cellectis (CLLS) Said on Its Q3 Earnings Call
Cellectis NASDAQ: CLLS said its cash runway is expected to extend into the second half of 2028 once its planned restructuring is fully implemented, giving the gene editing company time to reach anticipated initial clinical readouts for its two lead programs.
What Cellectis (CLLS) Said on Its Q3 Earnings Call
Neutral
GlobeNewsWire
9 days ago
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today reported financial results for the third quarter 2026 ended September 30, 2026, and provided a business update.
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
Neutral
GlobeNewsWire
12 days ago
Cellectis to Report Third Quarter Financial Results on November 12, 2026
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.
Cellectis to Report Third Quarter Financial Results on November 12, 2026
Neutral
GlobeNewsWire
26 days ago
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today announced the presentation of preclinical data supporting .HEAL-101, its in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia (sHTG), at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), being held October 27-30, 2026, in Hamburg, Germany.
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
Neutral
GlobeNewsWire
1 month ago
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) investors concerning the Company's possible violations of the federal securities laws.
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Neutral
GlobeNewsWire
1 month ago
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.
Price charts implemented using Lightweight Charts™